enGene Therapeutics Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
6.96
-0.24 (-3.33%)
Apr 28, 2026, 4:00 PM EDT - Market closed
enGene Therapeutics Income Statement
Financials in millions USD. Fiscal year is November - October.
Millions USD. Fiscal year is Nov - Oct.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Jan '26 Jan 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 |
| Selling, General & Admin | 30.98 | 28.69 | 23.98 | 9.6 | 3.96 | 3.41 | |
| Research & Development | 96.76 | 94.48 | 38.32 | 16.46 | 15.47 | 12.46 | |
| Operating Expenses | 127.74 | 123.17 | 62.3 | 26.06 | 19.43 | 15.87 | |
| Operating Income | -127.74 | -123.17 | -62.3 | -26.06 | -19.43 | -15.87 | |
| Interest Expense | -2.97 | -2.99 | -2.8 | -4.95 | -1.42 | -5.02 | |
| Interest & Investment Income | 9.44 | 9.43 | 10.41 | 1.12 | 0.13 | 0.03 | |
| Currency Exchange Gain (Loss) | -0.69 | -0.57 | -0.11 | -0.13 | -0.7 | -0.1 | |
| Other Non Operating Income (Expenses) | - | - | - | -10.57 | -3.02 | -4.2 | |
| EBT Excluding Unusual Items | -121.97 | -117.3 | -54.8 | -40.6 | -24.44 | -25.17 | |
| Other Unusual Items | -0.49 | - | -0.37 | -59.3 | - | 1.73 | |
| Pretax Income | -122.46 | -117.3 | -55.16 | -99.9 | -24.44 | -23.44 | |
| Income Tax Expense | -0.02 | - | -0.02 | 0.02 | 0.02 | - | |
| Net Income | -122.44 | -117.3 | -55.14 | -99.92 | -24.46 | -23.44 | |
| Preferred Dividends & Other Adjustments | - | - | - | 4.82 | 4.56 | -1.19 | |
| Net Income to Common | -122.44 | -117.3 | -55.14 | -104.74 | -29.02 | -22.25 | |
| Shares Outstanding (Basic) | 55 | 51 | 38 | 1 | 1 | 4 | |
| Shares Outstanding (Diluted) | 55 | 51 | 38 | 1 | 1 | 4 | |
| Shares Change (YoY) | 23.39% | 35.30% | 5355.08% | 5.72% | -81.61% | 28.93% | |
| EPS (Basic) | -2.22 | -2.29 | -1.46 | -151.22 | -44.30 | -6.25 | |
| EPS (Diluted) | -2.22 | -2.29 | -1.46 | -151.22 | -44.30 | -6.25 | |
| Free Cash Flow | -103.79 | -100.72 | -49.21 | -25.06 | -17.75 | -16.23 | |
| Free Cash Flow Per Share | -1.88 | -1.97 | -1.30 | -36.18 | -27.09 | -4.56 | |
| EBITDA | -127.14 | -122.66 | -61.97 | -25.89 | -19.19 | -15.6 | |
| D&A For EBITDA | 0.6 | 0.51 | 0.32 | 0.18 | 0.24 | 0.27 | |
| EBIT | -127.74 | -123.17 | -62.3 | -26.06 | -19.43 | -15.87 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.